Literature DB >> 14616338

Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures.

T Meyer1, I Nindl, T Schmook, C Ulrich, W Sterry, E Stockfleth.   

Abstract

Toll-like receptor (TLR)-7 agonists represent a new group of immune response modifiers, which include imiquimod and resiquimod (R-848). Topically applied imiquimod is used for the treatment of both external and perianal genital warts, and benign and malignant epithelial lesions. Based on the induction of interferons and other cytokines in vitro and in vivo, regression of epithelial lesions probably depends on induction of both innate and cellular immune responses. As clinical remission is not always associated with inflammation, other mechanisms may also be involved. Using two different assays for detection of apoptosis (TUNEL test and gel analysis of DNA fragmentation), we observed induction of apoptosis by imiquimod in human epithelial cell lines (HeLa S3) and keratinocytes (HaCaT, A431 cells), as well as in mouse fibroblasts (McCoy cells). These findings suggest that the mode of action of imiquimod to eliminate virus-infected, dysplastic or neoplastic epithelial cells may also include the induction of apoptotic processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616338     DOI: 10.1046/j.0366-077x.2003.05632.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

1.  Plasmacytoid dendritic cells lead the charge against tumors.

Authors:  Sonia Jiménez-Baranda; Inês Pires Silva; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

2.  Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies.

Authors:  Brenda J Weigel; Sarah Cooley; Todd DeFor; Daniel J Weisdorf; Angela Panoskaltsis-Mortari; Wei Chen; Bruce R Blazar; Jeffrey S Miller
Journal:  Am J Hematol       Date:  2012-06-20       Impact factor: 10.047

3.  Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.

Authors:  Zhengming Xiong; John R Ohlfest
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

4.  Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers.

Authors:  Melissa A Geller; Sarah Cooley; Peter A Argenta; Levi S Downs; Linda F Carson; Patricia L Judson; Rahel Ghebre; Brenda Weigel; Angela Panoskaltsis-Mortari; Julie Curtsinger; Jeffrey S Miller
Journal:  Cancer Immunol Immunother       Date:  2010-09-05       Impact factor: 6.968

Review 5.  Update on Keloid Management: Clinical and Basic Science Advances.

Authors:  Martha H Viera; Alejandra C Vivas; Brian Berman
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-10       Impact factor: 4.730

6.  Incorporation of low molecular weight molecules into alpha(2)-macroglobulin by nucleophilic exchange.

Authors:  Jennifer E Bond; George J Cianciolo; Salvatore V Pizzo
Journal:  Biochem Biophys Res Commun       Date:  2007-04-02       Impact factor: 3.575

7.  Current and emerging treatment strategies for the treatment of actinic keratosis.

Authors:  Joshua M Berlin
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-09-17

8.  Observational study of topical imiquimod immunotherapy in the treatment of difficult lentigo maligna.

Authors:  E E Craythorne; C M Lawrence
Journal:  Clin Med Oncol       Date:  2008-12-03

Review 9.  Toll-Like Receptor-Based Strategies for Cancer Immunotherapy.

Authors:  Saghar Pahlavanneshan; Ali Sayadmanesh; Hamidreza Ebrahimiyan; Mohsen Basiri
Journal:  J Immunol Res       Date:  2021-05-22       Impact factor: 4.818

10.  Polymorphisms in Toll-like receptor genes are associated with vitiligo.

Authors:  Tanel Traks; Maris Keermann; Maire Karelson; Ranno Rätsep; Ene Reimann; Helgi Silm; Eero Vasar; Sulev Kõks; Külli Kingo
Journal:  Front Genet       Date:  2015-09-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.